Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The Pain Biomarker Study
NCT03511846Phase 1Enrolling by invitation
- Sponsor
- UTHealth Houston
- Start
- Mar 2018
- Primary completion
- May 2028
- Modality
- Transdermal Patches, Inhalation Devices, Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of capsaicin 8% patch and oxygen in Primary headache disorder and lumbar radiculopathy (16 arms), sponsored by UTHealth Houston. Primary endpoints: Calcitonin gene-related peptide levels at 90 months and Tear fluid production at 90 months. Started Mar 2018; status: enrolling by invitation.
02
Drugs
capsaicin 8% patchoxygen
03
Conditions
Primary headache disorderlumbar radiculopathy
Beyond the preview
Go deeper on NCT03511846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03511846.